MTMichael A. Tsoukas

Michael A. Tsoukas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael A. Tsoukas has a total of 172 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes

    by Areesha Moiz, Kristian B. Filion, Aaron E. Samuels, Michael A. Tsoukas, Oriana H.Y. Yu, Tricia M. Peters, Mark J. Eisenberg

    Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for weight management, with a growing number of agents in the pipeline. This systematic review updates an earlier 2025 sy... Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for weight management. Purpose: To update our prior systematic review evaluating the efficacy and safety of G...

  • Open Access

    Antenatal Corticosteroids in Gestational Diabetes: A Systematic Review of Glycemic Response and Management Strategies

    by Alexandra Katz, Aidan Shulkin, Samantha Jacobson, Chella Price, Michael A. Tsoukas, Isabella Albanese, Agnieszka Majdan, Jill Pancer, Ariane Godbout, Kaberi Dasgupta, et al.

    Background: Antenatal corticosteroids (ACS) promote foetal lung maturation in pregnancies at risk of preterm birth; however, in gestational diabetes mellitus (GDM), they can exacerbate maternal glycemia and contribute to adverse neonatal outcomes. Clinical guidelines offer limited direction on optimal treatment adjustment. Objectives: To synthesize the evidence on glycaemic responses and management strategies following ACS exposure in individuals with GDM. Methods: A systematic review of Embase, MEDLINE and CENTRAL in October 2025 in accordance with PRISMA guidelines. Studies reporting on glycaemic outcomes and/or management strategies following ACS exposure in individuals with GDM were included. Results: Twenty studies were included. Maternal glycemia rose predictably after ACS, with hyperglycaemia typically emerging within 9–16 h, peaking over the subsequent 24–72 h and often persisting up to 5 days. Among individuals managed with medical nutrition therapy or oral hypoglycaemic agents at baseline, insulin initiation ranged from 13% to 91%. Among those already using insulin, 67%–88% required dose escalation, with mean increases typically ranging from 47% to 91%. Pregnancy‐adapted intravenous insulin (IVI) pathways reported higher time‐in‐range and fewer hyperglycaemic/hypoglycaemic events than adult IVI protocols. However, emerging evidence suggests that structured, pregnancy‐specific subcutaneous insulin protocols may achieve comparable or improved glycaemic control. Conclusions: ACS exposure in GDM is associated with a predictable but variable, transient deterioration in maternal glycaemia. GDM‐specific evidence suggests that structured pregnancy‐adapted monitoring and insulin‐adjustment pathways may help attenuate post‐ACS hyperglycaemia. However, the evidence remains heterogeneous and largely observational. Prospective studies are needed to validate GDM‐specific algorithms, clarify thresholds for insulin initiation or escalation and define indications for subcutaneous versus IVI.

  • Open Access

    The Effect of Canagliflozin Dose on Renal and Cardiovascular Outcomes in Type 2 Diabetes and High Cardiovascular Risk

    by Elias John Elenjickal, Frédéric Baroz, Philippe Boileau, Michael A. Tsoukas, Abhinav Sharma, Thomas A. Mavrakanas

    Introduction: Pharmacokinetic data suggest a potential dose‐dependent effect of sodium–glucose co‐transporter‐2 (SGLT‐2) inhibitors on surrogate markers of efficacy, but the impact of SGLT‐2 inhibitor dose on renal and cardiovascular outcomes remains uncertain. Methods: In this post hoc analysis, we evaluated the efficacy and safety of two canagliflozin doses (100 and 300 mg) on hard clinical endpoints using participant‐level data from the CANVAS randomised controlled trial (4330 patients). The primary outcome was a composite of doubling of serum creatinine, renal failure, or death due to renal cause. Secondary outcomes included a composite cardiovascular endpoint; hospitalisation for heart failure; all‐cause mortality; and progression or regression of albuminuria. Safety outcomes included serious hyperkalaemia and acute kidney injury. Cox proportional hazards models were used. Results: There was no significant difference in the composite renal endpoint between the two doses: hazard ratio (HR) 0.85; 95% confidence interval (CI) 0.38–1.89 ( p = 0.68). Both doses, however, were associated with significant reductions in the incidence of the primary renal endpoint compared with placebo: HR 0.49 (95% CI 0.25–0.95; p = 0.03) for 100 mg and HR 0.41 (95% CI 0.20–0.83; p = 0.01) for 300 mg. There was no difference between the two doses of the drug in any of the secondary endpoints. Importantly, no added safety concerns were identified with either dose. Conclusions: In this post hoc analysis of the CANVAS trial, we did not observe evidence of a dose‐dependent effect of canagliflozin on renal or cardiovascular outcomes. Both doses reduced the risk of kidney events versus placebo, suggesting clinical benefit at any dose.

  • Open Access

    Semaglutide and cardiovascular risk in type 1 diabetes: A predictive modelling analysis in a double‐blind, randomised, placebo‐controlled cross‐over trial

    by Luxcia Kugathasan, Michael A. Tsoukas, Massimo Nardone, Vikas S. Sridhar, Marcel H. A. Muskiet, David Z. I. Cherney, Ahmad Haidar, Melissa‐Rosina Pasqua

  • Open Access

    A systematic review of glucocorticoid use in type 1 diabetes: Glycaemic effects and clinical management strategies

    by Alexandra Katz, Aidan Shulkin, Asmaa Housni, Amélie Roy‐Fleming, Rémi Rabasa‐Lhoret, Jean‐Francois Yale, Michael A. Tsoukas, Tricia M. Peters, Anne‐Sophie Brazeau

    Glucocorticoids (GCs) are widely utilised for the treatment of inflammatory and autoimmune conditions but often precipitate significant hyperglycaemia. People with type 1 diabetes (PWT1D) may be particularly affected due to the challenges of adjusting insulin dosing, for which recommendations remain unclear. Our aim is to synthesise the evidence on the glycaemic effects of GCs in PWT1D across various formulations, doses and administration routes, and to outline management strategies. In August 2025, a systematic search of MEDLINE, Embase and CENTRAL was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta‐Analysis guidelines. Eligible studies included adult PWT1D exposed to GCs and reported glycaemic outcomes and/or management strategies. Twenty‐two studies were included, comprising 368 PWT1D. GC exposure was consistently associated with marked hyperglycaemia and increased insulin requirements. Oral and intravenous GC regimens required substantial insulin dose escalation, in many cases up to 70% from baseline. During pregnancy, antenatal corticosteroids were best managed with structured subcutaneous or intravenous insulin protocols. Local injectable GCs caused delayed but prolonged excursions and required careful blood glucose (BG) monitoring. Emerging data suggest that automated‐insulin delivery (AID) systems attenuate BG elevation but still require user intervention. Thus, GC therapy in PWT1D destabilises glycaemic management, though impact and timing vary by formulation, dose, administration route, patient‐specific factors and clinical context. Proactive, individualised insulin adjustments aligned with GC pharmacokinetics and frequent BG monitoring or continuous glucose monitor use represent the most practical current strategy. Further research is required to develop evidence‐based guidelines and to clarify the role of AID.


  • Inter- and intra-physician variability in insulin injection adjustments compared with Bayesian algorithm recommendations in type 1 diabetes

    by Alessandra Kobayati, Michael A. Tsoukas, Natasha Garfield, Laurent Legault, Melissa-Rosina Pasqua, Jean-François Yale, Sara J. Meltzer, Simon S. Wing, Stéphanie Michaud, Vanessa Tardio, et al.

    Aims/hypothesis There is an unmet need for automated insulin adjustments for multiple daily injections in type 1 diabetes under unsupervised use. We aimed to assess the McGill decision support system (DSS), which comprises a Bayesian algorithm, by comparing its automated insulin adjustments with those made by endocrinologists. Methods We surveyed 13 Canadian endocrinologists who made mock insulin adjustments in three separate parts on retrospective participants’ data. Part A (weekly data) and part C (biweekly data) compared the recommendations from physicians with those of the algorithm. Part B evaluated intra-physician variability by comparing the recommendations made by the same physician over time based on an identical dataset to part A. Results In part A, the agreement rate (mean [SD]) on the direction of weekly adjustments between the algorithm and physicians was non-inferior to the agreement rate between physicians for prandial bolus (55% [5] vs 56% [7], respectively; p=0.006) and basal insulin (48% [6] vs 51% [11], respectively; p=0.037). Low full disagreement rates on weekly adjustments were also comparable between the pairs for prandial bolus (3.9% [2.3] vs 4.1% [2.3], respectively; p=0.006) and basal insulin (10.6% [4.6] vs 9.2% [7.1], respectively; p=0.23). Similar rates were observed for biweekly insulin adjustments in part C. When comparing intra-physician decisions in part A with those in part B, on average, physicians fully agreed with themselves 66% (SD 7) and 67% (SD 7) of the time for prandial bolus and basal insulin adjustments, respectively. Conclusions/interpretation The direction of insulin adjustments was comparable between physicians and the McGill algorithm. The large intra-physician variability further emphasises the subjective nature of insulin management. Graphical Abstract

  • Open Access

    Changes to insulin requirements over time with semaglutide in adults with type 1 diabetes on insulin pump therapy: A post‐hoc analysis of a double‐blinded, randomised, crossover trial

    by Melissa‐Rosina Pasqua, Michael A. Tsoukas, Ahmad Haidar

    Background: There is little data on how semaglutide affects basal versus bolus insulin and dosing parameters in adults with type 1 diabetes on insulin pump therapy. Methods: This is a post‐hoc analysis of a double‐blinded, randomised, crossover trial assessing semaglutide (up to 1 mg) versus placebo during automated insulin delivery (AID). This analysis focuses on the first 11 of 15 weeks where participants used their routine pump therapy with continuous glucose monitoring (CGM), where remote follow‐ups were performed on days 7, 21, 32, 56, 63, and 77 (± 4 days). Changes in insulin requirements, carbohydrate input, and pump parameters over time compared to baseline were assessed, as well as the frequency of parameter adjustments. Results: Twenty‐six participants were included; 100% were using CGM and 81% using AID at baseline. Daily total and bolus insulin, along with carbohydrate input, were significantly reduced by day 7 and remained so, while basal was significantly reduced by day 32. By day 77, there was a median increase in carbohydrate ratios by 4.1% [−1.8, 7.7] and in correction factors by 11.2% [0.0, 20.8], and a reduction in pre‐programmed basal rates by 7.9% [−12.7, −4.2]. The median time spent in hypoglycemia was rarely >4% during these follow‐ups. Conclusions: Insulin needs decrease rapidly upon initiation of semaglutide use in type 1 diabetes on pump therapy, predominantly due to bolus changes from less carbohydrate consumption. While diabetes technology helps to reduce hypoglycemia, adjustments to pump dosing are still required.


  • A Pilot Outpatient Assessment of a Fully Closed-Loop Insulin and Pramlintide System

    by Madison Odabassian, Michael A. Tsoukas, Elisa Cohen, Melissa-Rosina Pasqua, Joanna Rutkowski, Ahmad Haidar

    Background: Type 1 diabetes is treated with exogenous insulin using multiple daily injections or insulin pumps. However, both strategies require carbohydrate counting for prandial insulin dosing, which is both burdensome and error prone. Methods: We conducted a pilot, randomized, controlled study to eliminate carbohydrate counting in adults (n = 12, 7 females, age 39.5 [15.1], HbA1c 7.4% [0.6]) using an automated insulin and pramlintide fully closed-loop system. The interventions included five arms during which participants underwent 14 hours of outpatient, free-living, supervised experiments of (1) faster aspart with carbohydrate counting (control), faster aspart and pramlintide without carbohydrate counting at (2) 8 µg/U and (3) 10 µg/U ratios, and aspart and pramlintide without carbohydrate counting at (4) 8 µg/U and (5) 10 µg/U ratios. Results: The median time in target range (3.9–10.0 mmol/L) with the control arm was 78.6 [65.3-92.9], compared with 76.2 [64.6-86.9] and 78.8 [68.8-86.0] with the fully closed-loop faster aspart and pramlintide systems at 8 and 10 µg/U ratios, respectively, and compared with 65.9 [59.9-83.6] and 77.4 [72.1-82.7] with the fully closed-loop aspart and pramlintide systems at 8 and 10 µg/U ratios, respectively. Times spent below 3.9 and 3.0 mmol/L were numerically higher with the fully closed-loop aspart and pramlintide systems than the control arm. None of the differences were statistically significant. Conclusions: This study suggests that automated insulin and pramlintide systems have the potential to alleviate carbohydrate counting without degrading time in range. A longer and larger study is underway.